Indy Economic Development

Congratulations to Eli Lilly and Company on completing its acquisition of Verve Therapeutics! This move strengthens Lilly’s growing portfolio in cardiometabolic disease and underscores Indianapolis’ continued leadership in advancing biotech innovation with global impact.

Verve’s pioneering work in gene editing—focused on creating one-time treatments for cardiovascular disease—aligns with Lilly’s bold mission to improve outcomes for people at high cardiovascular risk. https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk-302513948.html

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV)....

Major Investment News for !
Today, announced plans to invest up to $550 million in its Indianapolis operations—cementing our city’s role as a national hub for life sciences innovation.

The expansion will create hundreds of skilled local jobs, strengthen U.S. domestic manufacturing, and aupport millions living with diabetes through new continuous glucose monitoring technology.

Mayor Joe Hogsett and Indy Economic Development CEO Jim Schellinger joined Roche leaders to celebrate this milestone for our city and for American manufacturing.

With over 4,800 Roche employees already in Indy, today’s announcement deepens a decades-long commitment to growing talent, innovation, and impact right here on the northeast side.

More than just investment: this is about improving health outcomes and creating opportunity.